The USFDA has recently approved erdafitinib for adult patients with locally advanced or metastatic urothelial carcinoma with mutations in the fibroblast growth factor receptor (FGFR) 3 gene after systemic therapy. Erdafitinib is a kinase inhibitor that inhibits the enzymatic activities of FGFR genes. The approval was granted based on a clinical trial conducted on 266 urothelial cancer patients. Clinical trial In the clinical trial, erdafitinib significantly improved overall survival (12.1 vs.
7.8 months), progression-free survival (5.6 vs. 2.7 months), and objective response rate (35.3% vs. 8.5%) in patients compared to standard chemotherapy (docetaxel or vinflunine). Dosage and administration 8 mg; orally once daily Based on tolerability, the dose can be increased to 9 mg Adverse reactions Elevated phosphate, creatinine, alkaline phosphate, alanine aminotransferase, aspartate…
